Durvalumab (Imfinzi) combined with FLOT chemotherapy has been approved by the FDA as the first perioperative immunotherapy ...
The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first ...
The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...
The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...
Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking another major step in its $23 billion U.S. expansion plan. The site, the ...
Findings from the DYNAMIC-III trial, show that ctDNA testing can transform post-surgical care in Stage III colon cancer. Among more than 1,000 patients, ctDNA-negative individuals achieved 87% ...
ESMO’s new ELCAP guidance, published in Annals of Oncology, distills 23 consensus statements from 20 experts to safely integrate large language models into cancer care. It categorizes LLMs as ...
Results from the phase II LenCabo trial show that lenvatinib plus everolimus significantly prolonged progression-free survival to 15.7 months versus 10.2 months with cabozantinib in patients with ...
Five-year data from the Phase III NATALEE trial confirm that adjuvant ribociclib (Kisqali) plus endocrine therapy reduces recurrence risk by 28% in patients with HR+/HER2– early breast cancer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback